Investors readily calculate risk-adjusted net present value for individual therapeutic assets, whereas platforms are difficult to model financially. Unless a platform directly enhances probability of success, reduces development timelines, or cuts costs for clinical-stage drugs, venture investors often discount it merely as overhead expense.
Historically, neuroscience has suffered high clinical failure rates due to heterogeneous patient groups, complex pathologies, and subjective, squishy endpoints. Adopting oncology's playbook of validating objective biomarkers and stratifying patient sub-populations before clinical entry allows drug developers to de-risk trials and verify target engagement early.
A platform company must prove it can repeatedly produce unique assets with differentiated efficacy, safety, or delivery profiles that competitors cannot match. If a platform only enables a single drug program, it behaves as an asset company rather than justifying ongoing platform capital allocation.
CNS therapeutic delivery is a multi-layered hierarchy rather than just crossing the blood-brain barrier. Effective delivery requires achieving adequate exposure in specific anatomical brain regions, verifying target engagement within precise cell types, and achieving proper intracellular trafficking for advanced modalities like ASOs, siRNAs, and AAVs.
When evaluating early-stage ventures, investors rank the founding team's chemistry, self-awareness, and adaptability as primary criteria. The strongest founders recognize their own knowledge blind spots, aggressively seek complementary talent to address unknowns, and remain flexible enough to modify strong beliefs when presented with new data.
Traditional models like rodents, non-human primates, iPSCs, and brain organoids fail to replicate complex human brain architecture, vasculature, and disease biology. Reperfusing intact donor human brains preserves native blood-brain barriers, endogenous CSF production, and human-specific targets to directly generate human pharmacology preclinically.
